Triple Agonist
The newest of the three, adding a third pathway that may raise how many calories you burn. Retatrutide isn’t FDA-approved and is still in clinical trials. Ask Nicole whether it’s an option for you.
How It Works
Retatrutide works on the same two hormone pathways as Tirzepatide, GLP-1 and GIP, and adds a third: the glucagon receptor. That third pathway appears to modestly raise how many calories your body burns at rest, on top of turning down appetite.
It’s the newest of the three, with the least long-term data, so we start at a lower dose and raise it in small steps.
Is This Right for Me?
A third signaling pathway is the main reason people consider Retatrutide after trying the other two.
Retatrutide's trial data currently shows the largest average weight loss of the three medications we offer.
Long-term data is still coming in. You see Nicole monthly, and you can reach her directly when a question or side effect comes up.
Good to Know
In trials so far, people on higher doses lost roughly a quarter of their body weight on average. That’s the strongest result among the three medications we offer, though the research is still maturing.
One injection per week. Like the other two, it starts at a low dose and steps up slowly based on how you respond.
So far it looks similar to the other two: nausea, diarrhea, constipation, and feeling tired, mostly around dose increases. The class-wide risks, pancreatitis and gallbladder problems, apply here too. Because it’s newer, Nicole wants to hear about side effects early, and you can text her directly.
Is It Right for You?
Retatrutide isn’t FDA-approved and is still in clinical trials. Ask Nicole whether it’s an option for you. She’ll walk you through how it compares with Semaglutide and Tirzepatide, which have much more research behind them, and what makes sense for your goals.
Please don’t start Retatrutide if you’re pregnant, breastfeeding, or trying to get pregnant, or if you or a close family member has had medullary thyroid cancer or MEN2 (multiple endocrine neoplasia type 2). In rodent studies, GLP-1 medications caused thyroid C-cell tumors, and no one knows yet whether that happens in people, so those histories rule it out. If you’ve had pancreatitis or gallbladder problems, or you take insulin or another diabetes medication, tell us at your consult so we can talk it through.
If you’d rather stay with a medication that has a longer safety record, Semaglutide or Tirzepatide may suit you better. If you’re hoping to lose a few pounds fast before an event, a monthly program like this probably won’t feel like a good match. Whatever the reason, if it isn’t the right fit, we’ll tell you kindly and help you think through what might work instead.
Not FDA-approved as of October 2026. Results vary from person to person and aren’t guaranteed. This page is general information. Your consult is where we look at your own health history.
Comparing Your Options
Your dose is set individually, and we’ll talk through your options at your consult. Click a name to read the full page.
| Semaglutide | Tirzepatide | Retatrutide This Page | |
|---|---|---|---|
| Mechanism | Single pathway (GLP-1) | Dual pathway (GLP-1 + GIP) | Triple pathway (GLP-1 + GIP + glucagon) |
| Trial Results | ~15% body weight, on average | ~20.9% body weight, on average | Strongest results so far in trials |
| Price | $285–$400 / mo | $285–$800 / mo | Discussed at your consult |
| Best For | First-time GLP-1 patients | Plateaued on Semaglutide, or want a stronger start | Plateaued on the other two, comfortable with a newer option |
Good to Know
Wondering what’s known so far, or how it compares? Text us at (530) 201-2665.
Not FDA-approved as of October 2026. It’s the newest of the three, so we start at a lower dose. You get the same monthly check-ins as with the other two, plus direct access to Nicole for questions in between.
It isn’t FDA-approved, so many providers choose not to offer it yet.
It adds a third pathway, glucagon receptor activity, on top of the GLP-1 and GIP pathways Tirzepatide already uses. That third pathway appears to modestly raise how many calories you burn, in addition to lowering appetite.
Trial data so far shows side effects similar to the other two, mostly digestive. It has less long-term data than Semaglutide or Tirzepatide, so tell Nicole about any side effect when you first notice it. You can reach her directly between your monthly check-ins. The same cautions apply as for every GLP-1 medication; see who this isn’t for, above.
People who've plateaued on Semaglutide or Tirzepatide, or who want the strongest results shown in trials so far and are comfortable with something newer. We'll talk through whether that trade-off makes sense for you at your consult.
A similar pattern to the other two: nausea, diarrhea, constipation, and tiredness, mostly during dose increases, usually easing as your body adjusts. Call us if you have severe belly pain that won’t let up.
No. We don’t bill insurance for any of the three medications, Retatrutide included. You’ll know the exact monthly cost before you commit, and Cherry payment plans let you spread it out.
“I love Nicole! You will too! I am a very happy client!”
Stacy H. · Google Review
5.0 on Google · read all 27 reviews →Book a free 30-minute consult with Nicole. She’ll go over what the research shows so far, what’s still unknown, and how it compares with the other two for your history. By phone Monday through Friday, or in the Studio on Tue or Thu.
Book a Free 30-Min ConsultCurious About Retatrutide?
Nicole will walk you through whether it’s a fit, how it compares with Semaglutide and Tirzepatide, and what she’d recommend for your goals.
Have a question first? Call or text (530) 201-2665. We’re happy to help before you book.
Get In Touch
Questions, or ready to book? Reach out directly, or send a message and we’ll get back to you within 24 hours.
Payment Plans Available
Pay over time with Cherry. Checking takes about a minute and won’t affect your credit. 0% APR options for qualified clients. See what you qualify for →